Open access
Open access
Powered by Google Translator Translator

General Hematology

Review: Histiocytic disorders.

24 Jan, 2022 | 08:02h | UTC

Histiocytic disorders – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Histiocytic disorders (if the link is paywalled, try this one)

 

Commentary on Twitter

 

Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 Update.

21 Jan, 2022 | 09:53h | UTC

Perioperative Guidelines on Antiplatelet and Anticoagulant Agents: 2022 Update – Current Anesthesiology Reports

 

Expert consensus for plasma and platelet transfusion practice in critically ill children.

20 Jan, 2022 | 08:44h | UTC

Executive Summary of Recommendations and Expert Consensus for Plasma and Platelet Transfusion Practice in Critically Ill Children: From the Transfusion and Anemia EXpertise Initiative—Control/Avoidance of Bleeding (TAXI-CAB) – Pediatric Critical Care Medicine

 

RCT: In non–critically ill hospitalized patients with COVID-19, the use of a P2Y12 Inhibitor (ticagrelor in 63% of patients and clopidogrel in 37%) in addition to a therapeutic dose of heparin did not improve survival free of organ support compared to therapeutic heparin alone.

19 Jan, 2022 | 08:56h | UTC

Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Antiplatelet Therapy in Patients With COVID-19—More Is Less? – JAMA

Commentary: Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19 – HealthDay

 

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

18 Jan, 2022 | 09:41h | UTC

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021 – Annals of Internal Medicine

Editorial: The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia – Annals of Internal Medicine

 

Systematic Review: Restrictive transfusion thresholds can safely decrease transfusions by 41% across a broad range of clinical contexts.

14 Jan, 2022 | 08:18h | UTC

Transfusion thresholds for guiding red blood cell transfusion – Cochrane Library

Summary: Is it safe to use lower blood counts (haemoglobin levels) as a trigger for blood transfusion in order to give fewer blood transfusions? – Cochrane Library

Related:

RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy

Randomized trial: Liberal vs. restrictive transfusion thresholds in extremely low-birth-weight infants

Meta-Analysis: Effects of Restrictive vs. Liberal Transfusion Strategies on Longer-term Outcomes After Cardiac Surgery

Randomized Trial: In Patients Undergoing Cardiac Surgery, A Restrictive Transfusion Approach Does Not Increase the Risk of Acute Kidney Injury

Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials – Critical Care

Research: Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery

Transfusion Requirements After Cardiac Surgery: The TRACS Randomized Controlled Trial – JAMA

 

Commentary on Twitter

 

The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – in the absence of contraindications, use therapeutic-dose anticoagulation with low molecular weight heparin for hospitalized patients not in the ICU who have a D-dimer above the upper limit of normal.

12 Jan, 2022 | 09:11h | UTC

The COVID-19 Treatment Guidelines Panel’s Statement on Anticoagulation in Hospitalized Patients With COVID-19 – NIH COVID-19 Treatment Guidelines

 

RCT: Among patients younger than 21 years of age with provoked thromboembolism, anticoagulation for 6 weeks was non-inferior vs. 12 weeks on the risk of recurrence and bleeding events.

12 Jan, 2022 | 08:53h | UTC

Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Duration of Anticoagulant Treatment for Acute Provoked Venous Thromboembolism in Pediatric Patients – JAMA (free for a limited period)

 

RCT: Eltrombopag added to immunosuppression is associated with improved hematologic response vs. immunosuppression alone in previously untreated patients with severe aplastic anemia.

12 Jan, 2022 | 08:46h | UTC

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: New trial demonstrates improvements in immunosuppressive treatment of patients with severe aplastic anemia – European Society for Blood and Marrow Transplantation

 

Commentary on Twitter

 

RCT: Interferon-alpha vs. Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia.

12 Jan, 2022 | 08:35h | UTC

A Randomized, Phase 3, Trial of Interferon-α versus Hydroxyurea in Polycythemia Vera and Essential Thrombocythemia – Blood

 

Review: Management of coagulopathy in bleeding patients.

12 Jan, 2022 | 08:34h | UTC

Management of Coagulopathy in Bleeding Patients – Journal of Clinical Medicine

 

RCT: In children with sickle cell anemia, hydroxyurea in moderate doses (20 mg/kg per day) is not better than low doses (10 mg/kg per day) for primary stroke prevention.

11 Jan, 2022 | 02:10h | UTC

Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)

 

[Preprint] RCT: In symptomatic adults above 18 years positive for SARS-CoV-2, early outpatient treatment with high-titer convalescent plasma significantly reduced hospitalizations.

8 Jan, 2022 | 23:28h | UTC

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma – medRxiv

News release: Early Use of Convalescent Plasma May Help Outpatients with COVID-19 Avoid Hospitalization – Johns Hopkins Medicine

Commentary: Convalescent plasma shows renewed promise for COVID-19 in outpatient trial – Science

 

In a large retrospective cohort study of patients with atrial fibrillation 65 years or older, treatment with rivaroxaban compared with apixaban was associated with increased risk of major ischemic or hemorrhagic events.

8 Jan, 2022 | 22:37h | UTC

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation – JAMA

Commentary: Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study – TCTMD

Related:

Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation – American Journal of Medicine

Observational Study Suggests Apixaban May Be a Better Choice than Rivaroxaban for Patients with Atrial Fibrillation

 

Retrospective cohort study: In patients with venous thromboembolism (VTE), treatment with apixaban was associated with lower rates for recurrent VTE and bleeding compared to rivaroxaban.

8 Jan, 2022 | 22:36h | UTC

Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data – Annals of Internal Medicine

Commentaries:

Apixaban shows superior effectiveness, safety compared to rivaroxaban – ACP Internist

Recurrent VTE and Bleeding With Apixaban vs. Rivaroxaban – American College of Cardiology

 

RCT: Among patients hospitalized with COVID-19 at increased risk for venous thromboembolism, post-discharge thromboprophylaxis with Rivaroxaban for 35 days may improve outcomes.

17 Dec, 2021 | 09:50h | UTC

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial – The Lancet

Invited commentary: Anticoagulation in COVID-19 – The Lancet

 

Commentary on Twitter

 

How to recognize and manage COVID-19-associated coagulopathy.

13 Dec, 2021 | 09:45h | UTC

How to recognize and manage COVID-19-associated coagulopathy – Hematology, ASH Education Program

 

COVID-19 and thrombosis: searching for evidence.

13 Dec, 2021 | 09:47h | UTC

COVID-19 and thrombosis: searching for evidence – Hematology, ASH Education Program

 

Hematology, the ASH Education Program – series of review articles with clinical cases published annually by the American Society of Hematology.

13 Dec, 2021 | 08:45h | UTC

Homepage: Hematology, the ASH Education Program

 

Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician.

9 Dec, 2021 | 10:00h | UTC

Update in the diagnosis and management of acute pulmonary embolism for the non-respiratory physician – Clinical Medicine Journal

 

WHO recommends against the use of convalescent plasma to treat COVID-19.

8 Dec, 2021 | 10:24h | UTC

News Release: WHO recommends against the use of convalescent plasma to treat COVID-19 – World Health Organization

See Guidance: WHO’s living guidelines on COVID-19 therapeutics

Infographic: A living WHO guideline on drugs for covid-19 – The BMJ

 

Commentary on Twitter (thread – click for more)

 

ESC Position Paper: Optimal follow-up after acute pulmonary embolism.

8 Dec, 2021 | 10:02h | UTC

Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society – European Heart Journal

 

Commentary on Twitter

 

Another randomized trial showed convalescent plasma does not benefit patients hospitalized with Covid-19.

1 Dec, 2021 | 09:49h | UTC

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Related:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Commentary on Twitter

 

Review: Castleman disease.

26 Nov, 2021 | 09:49h | UTC

Castleman disease – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Castleman Disease (if the link is paywalled, try this one)

 

Review: Prevention and management of thrombosis in hospitalized patients with COVID-19 pneumonia.

26 Nov, 2021 | 08:44h | UTC

Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia – The Lancet Respiratory Medicine

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.